Abstract Library

#2725 Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients

Introduction: Surgery is the principal treatment for loco-regional gastroenteropancreatic (GEP) neuroendocrine tumors (NET). However, whether surgery is beneficial in high-grade neuroendocrine neoplasms (NEN) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN) is not known.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Pommergaard H

Authors: Pommergaard H, Nielsen K, Sorbye H, Federspiel B, Tabaksblat E,

Keywords: surgery, neuroendocrine carcinoma, MiNEN, neuroendocrine neoplasms, survival, gastroenteropancreatic,

#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours

Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sorbye H

Authors: Sorbye H, Meyer L, Mordal K, Myhre S, Thiis-Evensen E,

Keywords: Quality of life, small-intestinal neuroendocrine tumors, patient reported symptoms, coping, somatostatin analogue,

#1783 Gastroenteropancreatic High-Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 6291 Cases

Introduction: Knowledge about gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) is scarce given their low incidence rates and aggressive clinical behavior

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Dasari A, Mehta K, Sorbye H, Yao J,

Keywords: Grade 3, NE carcinoma,

#314 Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-Line Chemotherapy

Introduction: Patients with metastatic PDEC usually have a short survival. After first-line palliative chemotherapy, there are no established second-line treatments. Temozolomide has shown effect in other NETs.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Welin S, Sorby H, Sebjornsen S, Knappskog S, Busch C,

Keywords: chemotherapy, neuroendocrine cancer, PDEC, second-line, temozolomide,